SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit

NEW YORK — Rosen Law Firm, a global investor rights law firm, is urging individuals who purchased securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025 (the “Class Period”) to be aware of an important deadline in a securities fraud class action lawsuit. Investors who suffered losses during this period have the opportunity to seek appointment as lead plaintiff, the representative party who can help direct the litigation. The deadline to move the court for lead plaintiff status is January 16, 2026. Participation in the lawsuit does not require out‑of‑pocket costs, as fees are typically arranged on a contingency basis. Those interested in joining the class action or seeking more information can visit the Rosen Law Firm’s submission page or contact the firm directly for details on how to participate. This legal action highlights potential investor recovery for alleged misrepresentations in the company’s public disclosures during the specified period. #SkyeBioscience #SecuritiesFraud #ClassAction #InvestorRights #SlimScan #GrowthStocks #CANSLIM